Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06357741

Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.

Key Details

Gender

All

Age Range

45 Years - 75 Years

Study Type

OBSERVATIONAL

Enrollment

30

Start Date

2021-08-01

Completion Date

2025-12-31

Last Updated

2025-04-09

Healthy Volunteers

Yes

Interventions

DRUG

Denosumab

Desumumab, 60mg single injection

Locations (1)

Wuhan Union Hospital

Wuhan, Hubei, China